drugset / Trial / NCT05736757

Application of tPA in Suprachoroidal and Subretinal Hemorrhage

NCT05736757

RandomizedParallel-groupOpen-labelTreatment

Summary

Severe ocular rupture may be accompanied by suprachoroidal hemorrhage, or subretinal hemorrhage, or with suprachoroidal hemorrhage and subretinal hemorrhage. The suprachoroidal hemorrhage needs to be drained as soon as possible. In the process of waiting for the spontaneous liquefaction of hemorrhage, uncontrollable elevated intraocular pressure may occur, resulting in optic nerve injury, optic nerve atrophy, and visual loss. Tissue plasminogen activator can promote the liquefaction of blood clots. Studies have found that local application of tissue plasminogen activator in the suprachoroidal space can promote the liquefaction of the hemorrhage. Local application of tissue fibrinogen activator under the retina can promote the liquefaction of subretinal hemorrhage.

Timeline

Start
2022-12-01
Primary completion
2023-04-01
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 50 ug Other

Indications

No indication recorded.